entity

Amyloid

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Amyloid: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

7024Connections

9Hypotheses

24Analyses

16Outgoing

50Incoming

Summary

Amyloid is an entity related to neurodegeneration research. Key relationships include: activates, associated with, interacts with. Associated with ALS, Aging, Als. Connected to 539 entities in the SciDEX knowledge graph.

View on Wiki →

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    Amyloid["Amyloid"] -->|"interacts"| Lecanemab["Lecanemab"]
    BACE1["BACE1"] -.->|"inhibits"| Amyloid["Amyloid"]
    BACE1_1["BACE1"] -->|"activates"| Amyloid["Amyloid"]
    Aducanumab["Aducanumab"] -.->|"inhibits"| Amyloid["Amyloid"]
    Aducanumab_2["Aducanumab"] -->|"biomarker for"| Amyloid["Amyloid"]
    style Amyloid fill:#006494,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (3129)

Target	Relation	Type	Str
Neurodegeneration	contributes_to	process	0.85
Lecanemab	interacts_with	entity	0.70
Spinal Muscular Atrophy	therapeutic_target	disease	0.60
Diabetes	therapeutic_target	disease	0.60
Wnt	therapeutic_target	pathway	0.55
Necroptosis Pathway	therapeutic_target	pathway	0.55
Ampk Signaling	activates	pathway	0.55
Oxidative Stress	transports	pathway	0.55
Dna Methylation	activates	pathway	0.55
Neuron	associated_with	cell_type	0.50
Astrocyte	associated_with	cell_type	0.50
Microglia	associated_with	cell_type	0.50
Oligodendrocyte	associated_with	cell_type	0.50
Stem Cell	associated_with	cell_type	0.50
Neural Stem Cell	associated_with	cell_type	0.50
T Cell	associated_with	cell_type	0.50

Incoming (3895)

Source	Relation	Type	Str
Protein Aggregation	associated_with	process	0.95
Air Pollution	causes	compound	0.90
TDP43	interacts_with	protein	0.90
PI3K	regulates	protein	0.85
AKT	regulates	protein	0.85
APOE4	risk_factor_for	gene	0.85
BACE1	inhibits	entity	0.70
BACE1	activates	entity	0.70
Aducanumab	inhibits	entity	0.70
Aducanumab	biomarker_for	entity	0.70
Aducanumab	implicated_in	entity	0.70
Lecanemab	activates	entity	0.70
Lecanemab	inhibits	entity	0.70
Lecanemab	interacts_with	entity	0.70
A2M	interacts_with	gene	0.60
APH1B	interacts_with	gene	0.60
APOE	interacts_with	gene	0.60
APP	contributes_to	gene	0.60
DAPK1	interacts_with	gene	0.60
DHCR24	interacts_with	gene	0.60
EIF2AK2	interacts_with	gene	0.60
FAS	interacts_with	gene	0.60
HMGCR	interacts_with	gene	0.60
HSPG2	interacts_with	gene	0.60
IL1B	interacts_with	gene	0.60
IL6	interacts_with	gene	0.60
LMNA	interacts_with	gene	0.60
MAPT	interacts_with	gene	0.60
MITOCHONDRIAL DNA	interacts_with	gene	0.60
NCSTN	interacts_with	gene	0.60
PARP1	interacts_with	gene	0.60
PEN2	interacts_with	gene	0.60
PSEN1	interacts_with	gene	0.60
PSEN2	interacts_with	gene	0.60
SREBF1	interacts_with	gene	0.60
TNF	interacts_with	gene	0.60
C1QA	activates	gene	0.60
CTSB	activates	gene	0.60
GRN	activates	gene	0.60
SPP1	activates	gene	0.60
GPNMB	associated_with	gene	0.60
NPTX2	associated_with	gene	0.60
NTN1	associated_with	gene	0.60
VGF	associated_with	gene	0.60
JUN	associated_with	gene	0.60
NTN1	interacts_with	gene	0.60
NTN3	interacts_with	gene	0.60
SNRNP70	interacts_with	gene	0.60
TARDBP	interacts_with	gene	0.60
APOE	associated_with	gene	0.60

Targeting Hypotheses (9)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Closed-loop optogenetic targeting PV interneurons to restore	0.633	Alzheimer's disease	Circuit-level neural dynamics in neurode
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.610	-	Do β-amyloid plaques and neurofibrillary
Direct Toxicity Hypothesis: β-Amyloid Directly Impairs Choli	0.600	-	Do β-amyloid plaques and neurofibrillary
H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from	0.588	neurodegeneration	How does APOE4's beneficial immune funct
CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-S	0.576	neurodegeneration	What are the cell-type-specific transcri

Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in	0.458	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro
Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in	0.456	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro
Test: TREM2 enhances amyloid clearance	0.405	-	-
Microglial ACE Enhancement for Amyloid Clearance	0.399	neurodegeneration	Gene expression changes in aging mouse b

Mentioning Analyses (24)

Scientific analyses that reference this entity

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clin [PMID:41324786]	Abushakra S, Doraiswamy PM, Hey JA, Tosu	CNS drugs	2026
Adverse childhood experiences and cardiometabolic risk factors in people with bi [PMID:40935250]	Turner A, Kuperberg M, McGovern H, Wrobe	J Affect Disord	2026
Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomark [PMID:41198173]	Prasad R, Adu-Rutledge Y, Ziani B, Floyd	Gut	2026
Amyloidosis of bridging veins is a pathologic feature of Alzheimer's disease. [PMID:41329157]	Smyth LCD, Verhaege D, Standen-Bloom E,	J Exp Med	2026
A minimally invasive dried blood spot biomarker test for the detection of Alzhei [PMID:41491101]	Huber H, Montoliu-Gaya L, Brum WS, Vávra	Nat Med	2026
[Polypharmacy and nephrotoxicity]. [PMID:41535444]	Czock D, Ebinger K, Sommerer C	Inn Med (Heidelb)	2026
Association between sleep duration and fluid biomarkers of Alzheimer's disease: [PMID:41610733]	Young VM, Zeynoun J, Ruiz Laza A, Salard	Sleep Med Rev	2026
Long-term amyloid PET and MRI outcomes in a menopausal hormone therapy trial. [PMID:41618732]	Kantarci K, Kara F, Tosakulwong N, Fough	Alzheimers Dement	2026
Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean comm [PMID:41691306]	Orellana P, Henríquez F, Cabral-Miranda	Alzheimers Res Ther	2026
Neuro-renin-angiotensin-aldosterone system axis in alzheimer's disease: from mol [PMID:41706377]	Singh G, Maparu K, Aran KR	Metab Brain Dis	2026
Renin-angiotensin system blockade attenuates brain mitochondrial dysfunction, ox [PMID:41883437]	García Menéndez S, Inserra F, de Cavanag	World J Exp Med	2026
Association Between ACE (I/D) Polymorphism and Essential Hypertension (EH): An U [PMID:41899774]	Smallwood A, Akam E, Hunter DJ, Singh M,	Int J Environ Res Public Healt	2026
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR): a rand [PMID:41932694]	Pepine CJ, Handberg E, Cooper-DeHoff R,	Open Heart	2026
Renin-Angiotensin-Aldosterone Medication Use and Outcomes in Injured Patients Re [PMID:41936145]	Werenski HE, Diz DI, Chappell MC, Hoth J	J Surg Res	2026
Characteristics of reproductive tract microbiota in health and disease. [PMID:41936969]	Han Q, Wang N, Feng T, Li YY, Zhu Z et a	Microb Pathog	2026
Novel_circ_002651 regulates the immune defense of eastern honeybee larvae agains [PMID:41940497]	Zhang K, Wang F, Fan N, Fan X, Wu T et a	Virulence	2026
Safety and tolerability of the ACE-inhibitor lisinopril among Nigerian adults wi [PMID:41945136]	Dankishiya FS, Muhammad H, Wudil UJ, Mus	Naunyn Schmiedebergs Arch Phar	2026
Ace in the hole: playing cards show the role of order and magnitude in the SNARC [PMID:41945148]	Mingolo S, Prpic V, Cipora K, Bilotta E,	Psychol Res	2026
Feasibility of implementing an auditory rehabilitation program for older adults [PMID:41945417]	Torrente MC, Vasquez C, Bravo R, Miranda	Acta Otolaryngol	2026
Spatial distribution and health risk assessment of heavy metals in soils around [PMID:41954659]	Tengbeh AS, Akande IO, Offor CC, Abdulai	Environ Geochem Health	2026

Amyloid

Understanding Entity Pages

Summary

Wiki Pages (21)

PMN310 Anti-Amyloid for AD (NCT06750432)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Pathway Diagram

Outgoing (3129)

Incoming (3895)

Targeting Hypotheses (9)

Mentioning Analyses (24)

Are interneuron oscillation deficits compensatory responses or primary pathologi

What molecular mechanisms link elevated sphingomyelin synthase activity to incre

What molecular mechanisms explain how apoE promotes cerebral amyloid angiopathy

What signals trigger microglia to specifically recognize and phagocytose LC axon

Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in

How does HDAC1/2 deletion specifically enhance microglial amyloid phagocytosis c

Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD

Do β-amyloid plaques and neurofibrillary tangles cause or result from cholinergi

Extracellular vesicle biomarkers for early AD detection

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?

What evidence supports Cdk5 activation as THE primary cause of AD versus other e

Does SPP1-mediated synaptic engulfment represent beneficial clearance or patholo

How do perivascular cells specifically recognize and respond to amyloid-β to upr

Quantitative proteomics of the aging synapse in early Alzheimer disease

Human connectome alterations and network-level dysfunction in Alzheimer disease

Lipid metabolism dysregulation and membrane integrity in Alzheimer disease

Extracellular vesicle biomarkers for early AD detection

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

APOE4 structural biology and therapeutic targeting strategies

Blood-brain barrier transport mechanisms for antibody therapeutics

Lipid raft composition changes in synaptic neurodegeneration

Related Papers (20)

Amyloid

Understanding Entity Pages

Summary

Wiki Pages (21)

PMN310 Anti-Amyloid for AD (NCT06750432)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Parkinson's Disease

Sleep and Circadian Dysfunction in Alzheimer's Disease

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

primary-progressive-aphasia

CBS/PSP Supplements Guide

Atypical Parkinsonism

Parthanatos in Neurodegeneration

calcium-dysregulation-comparison

Alpha-Synuclein Pathology

Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

Alzheimer's Disease Mechanism Index

Corticobasal Degeneration (CBD)

nhp-validation-animal-model

Neuroresilience Mechanisms and Evidence

Pathway Diagram

Outgoing (3129)

Incoming (3895)

Targeting Hypotheses (9)

Mentioning Analyses (24)

Are interneuron oscillation deficits compensatory responses or primary pathologi

What molecular mechanisms link elevated sphingomyelin synthase activity to incre

What molecular mechanisms explain how apoE promotes cerebral amyloid angiopathy

What signals trigger microglia to specifically recognize and phagocytose LC axon

Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in

How does HDAC1/2 deletion specifically enhance microglial amyloid phagocytosis c

Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD

Do β-amyloid plaques and neurofibrillary tangles cause or result from cholinergi

Extracellular vesicle biomarkers for early AD detection

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?

What evidence supports Cdk5 activation as THE primary cause of AD versus other e

Does SPP1-mediated synaptic engulfment represent beneficial clearance or patholo

How do perivascular cells specifically recognize and respond to amyloid-β to upr

Quantitative proteomics of the aging synapse in early Alzheimer disease

Human connectome alterations and network-level dysfunction in Alzheimer disease

Lipid metabolism dysregulation and membrane integrity in Alzheimer disease

Extracellular vesicle biomarkers for early AD detection

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

APOE4 structural biology and therapeutic targeting strategies

Blood-brain barrier transport mechanisms for antibody therapeutics

Lipid raft composition changes in synaptic neurodegeneration

Related Papers (20)